At a threshold set a 90% sensitivity, we obtained 96% NPV in CI and 32% PPV providing a cohort enriched three fold for the Advanced AD stage suggesting a similar potential tau PET cost saving when creating a high tau cohort. The gene discussed is MAPT; the disease is Alzheimer disease.